Genpact Limited SEC Filings

Genpact disclosed the appointment of Mr. Radesca as Senior Vice President and Chief Accounting Officer. The filing states he will receive a base salary, annual bonus opportunities, and equity awards appropriate to his role, and will be eligible for Company-sponsored benefits such as health, disability, and life insurance. The company disclosed there are no arrangements or understandings with other persons regarding his appointment, no family relationships with any director or executive officer, and no transactions in the last fiscal year (and none proposed) that would trigger related‑party disclosure under Regulation S-K Item 404(a).

Insider transactions by Genpact Ltd (G): Senior Vice President and CHRO Piyush Mehta executed multiple transactions on 09/12/2025. He acquired 50,000 common shares at $31.50, and sold 50,000 shares and 26,902 shares at weighted-average prices of $42.58 (sales ranged from $42.42 to $42.73 and $42.42 to $42.70 respectively). After these transactions he beneficially owns 134,880 common shares. The filing notes he holds 10,222 shares under the ESPP (including 284 shares acquired since his prior Form 4). The Form 4 was signed by an attorney-in-fact on 09/15/2025.

Insider transactions by Genpact Ltd director and CEO Balkrishan Kalra. On 09/11/2025 Mr. Kalra sold 15,000 common shares at a weighted-average price of approximately $43.39 and sold 40,000 common shares at a weighted-average price of approximately $43.35, reducing his reported beneficial ownership to 295,246 shares. On the same date he acquired 40,000 common shares by exercising employee stock options at a $27.65 exercise price, bringing his beneficial ownership to 335,246 shares before the net sales shown. The Form 4 shows the option originally vested in two tranches (50% on 01/10/2019 and the remainder on 01/10/2021) and lists 40,000 underlying shares exercised with 2,800 derivative securities remaining reported as beneficially owned. Transactions were signed by an attorney-in-fact on 09/15/2025.

Genpact Ltd. filing a Form 144 shows a proposed sale of 76,902 common shares, with an aggregate market value of $3,274,240.31, to be executed approximately on 09/12/2025 on the NYSE. The broker listed is Morgan Stanley Smith Barney LLC. The filing itemizes how the securities were acquired: 26,902 performance shares granted on 01/10/2022 and 50,000 shares from a stock option exercise on 09/12/2025 paid in cash. The filing reports nothing to report for securities sold during the past three months. The signer attests they have no undisclosed material adverse information about the issuer.

Genpact Limited (G) officer or insider filed a Form 144 to sell 55,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,384,883.50 and an approximate sale date of 09/11/2025. The filing reports 174,270,076 shares outstanding for the issuer, implying the notice covers a small fraction of outstanding stock.

The securities to be sold were acquired partly by a stock option exercise on 09/11/2025 (40,000 shares, paid in cash) and partly as performance shares granted 01/10/2022 (15,000 shares). The filer states there were no shares sold in the past three months and attests they have no undisclosed material adverse information.

Donald J. Klunk, identified as Chief Accounting Officer, reported two non-derivative transactions in Genpact Limited (G). On 09/02/2025 1,468 shares were withheld for taxes upon vesting of restricted share units at a price of $45.34, leaving 10,135 shares beneficially owned after that transaction. On 09/03/2025 he sold 2,695 shares at $44.77, leaving 7,440 shares beneficially owned following the sale. The filing notes 252 shares were acquired under the Genpact Employee Stock Purchase Plan since his prior Form 4 on March 13, 2025, and he currently holds 673 ESPP shares. The form is signed by an attorney-in-fact on 09/04/2025.

Genpact Limited (G) notice: an individual who received 2,695 restricted common shares from the issuer on 08/31/2025 intends to sell those shares on or about 09/03/2025. The filer lists Morgan Stanley Smith Barney LLC as the broker and values the shares' aggregate market value at $120,641.68 based on outstanding common shares of 174,270,076. The filing reports no other sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Genpact Limited (G) insider transaction: Sameer Dewan, Senior Vice President, reported selling 20,078 common shares on 08/28/2025 at $45 per share, leaving him with 89,148 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing shows a direct disposition of shares and does not disclose any derivative transactions or a 10b5-1 plan.